Baker Bros. Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Baker Bros. Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-75,357	Closed	-$2.52M	–	124
2016 Q4	$2.52M	Hold	75,357	–	–	0.02%	85
2016 Q3	$2M	Hold	75,357	–	–	0.02%	96
2016 Q2	$1.66M	Hold	75,357	–	–	0.02%	105
2016 Q1	$2.21M	Hold	75,357	–	–	0.02%	98
2015 Q4	$2.49M	Hold	75,357	–	–	0.02%	101
2015 Q3	$2.72M	Hold	75,357	–	–	0.03%	94
2015 Q2	$3.39M	Hold	75,357	–	–	0.03%	88
2015 Q1	$2.31M	Hold	75,357	–	–	0.02%	100
2014 Q4	$3.83M	Hold	75,357	–	–	0.04%	80
2014 Q3	$2.98M	Hold	75,357	–	–	0.04%	79
2014 Q2	$3.25M	Sell	75,357 -5,600	-7%	-$214K	0.04%	81
2014 Q1	$3.24M	Sell	80,957 -28,140	-26%	-$1.02M	0.04%	83
2013 Q4	$2.98M	Sell	109,097 -15,903	-13%	-$385K	0.04%	73
2013 Q3	$2.87M	Hold	125,000	–	–	0.04%	69
2013 Q2	$2.21M	Buy	+125,000	New	+$2.44M	0.04%	61

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

MCM

Matarin Capital Management New York $409M AUM 33.03% 1-Year Est. Return

Baker Bros. Advisors's ENTA Position: Q1 2017 in Review

Baker Bros. Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q1 2017, closing a stake of 75,357 shares — an estimated $2.52M sold.

Baker Bros. Advisors first reported a position in ENTA in Q2 2013 and held it in 15 quarters. The position peaked at $3.83M in Q4 2014. 126 funds tracked by Wall St. Rank hold ENTA as of Q1 2017.

Baker Bros. Advisors reported no remaining Enanta Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Baker Bros. Advisors sold 75,357 Enanta Pharmaceuticals shares in Q1 2017, an estimated $2.52M.
Baker Bros. Advisors first reported a position in Enanta Pharmaceuticals in Q2 2013 and held it in 15 quarters.
Baker Bros. Advisors's Enanta Pharmaceuticals position peaked at $3.83M in Q4 2014.
126 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2017.

Based on Baker Bros. Advisors's 13F filing for Q1 2017, filed 15 May 2017.